 Established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals, Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery of a new class of high-impact medicines based on microRNAs. Its patent estate includes discoveries specific to microRNA sequences, therapeutic uses and drug designs, as well as over 600 patents and more than 300 pending patent applications pertaining primarily to chemical modifications of oligonucleotides targeting microRNA for therapeutic applications. The company s scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research. It advances microRNA therapeutics in several areas, including hepatitis C infection, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases and metabolic diseases. The company has strategic alliance with Sanofi-Aventis and GlaxoSmithKline.
|
